Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Medifast, Inc.NYSE: MED
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA dips below year-ago levels
Q1 FY2026 EBITDA of $1.54M fell 59.5% year over year, behind the +16.2% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at -70.8% a year.
Context
- EBITDA amounted to 1.3% of revenue in FY2025, down 1.5 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $2.71M (-44.3%) for the fiscal year ending Dec 2026, a step up from the -70.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.54M+152.9% QoQ
- Last fiscal yearDec 2025
- $4.86M-70.5% YoY
- LTMMar 2026
- $6.34M+16.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.5% | -155.2% | -95.7 pp |
| 1 year | -70.5% | -44.3% | +26.3 pp |
| 3-year CAGR | -70.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 4.86M USD
- Year-over-year change
- -70.5%
- 4-year CAGR
- -61.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.86M | -70.5% |
| FY2024 | 2024-12-31 | 16.49M | -88.4% |
| FY2023 | 2023-12-31 | 141.9M | -27.5% |
| FY2022 | 2022-12-31 | 195.74M | -12.2% |
| FY2021 | 2021-12-31 | 222.94M | — |
EBITDA vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.2% is the 4th highest of 10, against a peer median of +6.2%.
- EBITDA amounts to 1.8% of revenue for MED, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $71.37M USD | +7.9% | +15.9% | 9.3% | |
| LTM May 2026 | $61.91M USD | -50.3% | -20.5% | 6.3% | |
| FY2025 | HK$30.75M HKD | -75.3% | -35.4% | 6.7% | |
| LTM Jan 2026 | $26.69M USD | +75.6% | +191.8% | 9.3% | |
| LTM Feb 2026 | $17.97M USD | +24851.4% | -26.4% | 5.4% | |
| LTM Mar 2026 | $6.34M USD | +16.2% | -70.8% | 1.8% | |
| LTM Mar 2026 | -$296K USD | -104.1% | — | 0.0% | |
| LTM Mar 2026 | -$6.58M USD | +25.2% | — | 7.4% | |
| LTM Mar 2026 | -$41.72M USD | -325.6% | — | 16.5% | |
AIIORobo.ai Inc. | FY2025 | -$156.14M USD | +6.2% | — | 16436.0% |
| Peer median (excluding MED) | — | +6.2% | -20.5% | 7.4% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.